Antihypertensive drug therapy in the third millennium: are there benefits beyond blood pressure?
Bakir
S E
SE
UAB Vascular Biology & Hypertension Program, Room 1047 ZRB, 703 South 19th Street, Birmingham, AL 35294, USA. sbakir@uab.edu
Oparil
S
S
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000145:classification / Q000627:therapeutic use*; D001581:Benzothiadiazines; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002986:Clinical Trials as Topic; D016001:Confidence Intervals; D004232:Diuretics; D005260:Female; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000188:drug therapy*; D008297:Male; D012307:Risk Factors; D012737:Sex Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D015996:Survival Rate
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors